Alector announced the following additions to its board as independent directors: David Wehner, Chief Financial Officer of Facebook; Richard Scheller, Ph.D., Chief Scientific Officer of 23andMe; and Louis J. Lavigne, Jr. former Executive Vice President and Chief Financial Officer of Genentech. Mr. Wehner brings extensive financial and operational experience to Alector. Prior to his current position as chief financial officer of Facebook, Mr. Wehner served as vice president of corporate finance and business planning at Facebook. Dr. Scheller is a preeminent neuroscientist and experienced drug development leader. Prior to 23andMe, he served as executive vice president and head of Genentech Research and Early Development, and as a member of both the Genentech and Roche executive committees. Mr. Lavigne has extensive life science experience. In 2005, he retired from his position as executive vice president and chief financial officer of Genentech Inc., where he had served in roles of increasing responsibility since 1982. He currently serves on the boards of Accuray Inc., Assertio Inc., DocuSign Inc., Zynga Inc., Rodan & Fields, LLC, and Puppet Inc.Mr. Lavigne also previously served on the boards of Allergan Inc., BMC Software Inc., and SafeNet Inc. Mr. Lavigne is a member and former chairman of the UCSF Benioff Children’s Hospitals board of directors and the UCSF Benioff Children’s Hospitals Foundation.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration diseases. The Company is engaged in developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its product candidates: latozinemab (AL001), AL002, and AL101, are in clinical development. Its immune-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimerâs disease and genetically defined frontotemporal dementia patient populations. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients.
ALECTOR, INC. 
